UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in Repligen Co. (NASDAQ:RGEN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 235,343 shares of the biotechnology company's stock after purchasing an additional 26,733 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.42% of Repligen worth $33,875,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Signaturefd LLC increased its stake in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter worth $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen during the fourth quarter worth $40,000. Finally, Global Retirement Partners LLC increased its stake in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RGEN shares. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Repligen Stock Down 3.8%

NASDAQ:RGEN traded down $4.66 during midday trading on Friday, reaching $117.66. The company had a trading volume of 1,145,832 shares, compared to its average volume of 743,182. The firm has a market capitalization of $6.61 billion, a price-to-earnings ratio of -230.71, a PEG ratio of 4.54 and a beta of 1.21. The stock's fifty day simple moving average is $128.09 and its 200-day simple moving average is $143.64. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $0.28 earnings per share. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.